4/25/2011

Pfizer confirmed that one of four deaths during a clinical study of tofacitinib, a drug candidate for rheumatoid arthritis, was related to the drug. The company said tofacitinib-related mortality across several trials "is within the range of rates reported for biologic therapies" for the condition. Pfizer aims to market tofacitinib as an alternative to infused or injected treatments, such as Abbott Laboratories' Humira.

Related Summaries